ET-901 is under clinical development by EdiGene and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Splenic Marginal Zone B-Cell Lymphoma ...

TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82 ...

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white ...

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white blood ...

mantle cell lymphoma, and marginal zone lymphoma. This first patient to be dosed was treated at Sarah Cannon Research Institute at Colorado Blood Cancer Institute in Denver, Colorado. "The initiation ...

Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or relapsed large B-cell lymphoma in adults ... trials in the treatment of high-risk ...

are crucial regulators in both physiologic homing of B-cells and in B-cell lymphomagenesis in the skin. These signals support the development of indolent subtypes of primary cutaneous marginal zone ...

What Is Lymphoma? Lymphoma is a cancer of the lymphoid tissue, which includes both cells and organs. It affects the same organs of the lymphatic system (thymus, bone marrow, lymph nodes, spleen). But ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.